Exploration of Mediators Associated with Myocardial Remodelling in Feline Hypertrophic Cardiomyopathy.
Wan-Ching ChengCharlotte LawsonHui-Hsuan LiuLois WilkieMelanie J DobromylskyjVirginia Luis FuentesJayesh DudhiaDavid J ConnollyPublished in: Animals : an open access journal from MDPI (2023)
Hypertrophic cardiomyopathy (HCM) affects both humans and cats and exhibits considerable interspecies similarities that are exemplified by underlying pathological processes and clinical presentation to the extent that developments in the human field may have direct relevance to the feline disease. Characteristic changes on histological examination include cardiomyocyte hypertrophy and interstitial and replacement fibrosis. Clinically, HCM is characterised by significant diastolic dysfunction due to a reduction in ventricular compliance and relaxation associated with extracellular matrix (ECM) remodelling and the development of ventricular hypertrophy. Studies in rodent models and human HCM patients have identified key protein mediators implicated in these pathological changes, including lumican, lysyl oxidase and TGF-β isoforms. We therefore sought to quantify and describe the cellular location of these mediators in the left ventricular myocardium of cats with HCM and investigate their relationship with the quantity and structural composition of the ECM. We identified increased myocardial content of lumican, LOX and TGF-β2 mainly attributed to their increased expression within cardiomyocytes in HCM cats compared to control cats. Furthermore, we found strong correlations between the expressions of these mediators that is compatible with their role as important components of cellular pathways promoting remodelling of the left ventricular myocardium. Fibrosis and hypertrophy are important pathological changes in feline HCM, and a greater understanding of the mechanisms driving this pathology may facilitate the identification of potential therapies.
Keyphrases
- hypertrophic cardiomyopathy
- left ventricular
- extracellular matrix
- endothelial cells
- heart failure
- cardiac resynchronization therapy
- acute myocardial infarction
- left atrial
- mitral valve
- aortic stenosis
- end stage renal disease
- ejection fraction
- induced pluripotent stem cells
- newly diagnosed
- pluripotent stem cells
- poor prognosis
- binding protein
- peritoneal dialysis
- coronary artery disease
- blood pressure
- small molecule
- atrial fibrillation
- case control
- signaling pathway
- single molecule
- protein protein